MENA 2019-nCoV testing kit Market

XYZ 2020-07-06 15:16

In2020, over 13 million persons in MENA were tested until June 2020. MENA demandfor 2019-nCoV testing kit will be nearly 30 million units and sales revenuewill be about 200 million USD.

Laboratory testing for SARS-CoV-2 (severeacute respiratory syndrome coronavirus 2) includes methods that detect thepresence of virus and those that detect antibodies produced in response toinfection. As of 21st March 2020, the CDC recommends RT-PCR for initialscreening. Due to limited testing, as of March 2020 no countries had reliabledata on the prevalence of the virus in their population. So, due to risingprevalence of patient against testing of viral disease the demand for Covid-19test kits will increases over the period of time.


Thereare mainly ten 2019-nCoV testing kit manufacturers in MENA including PishtazTeb, Anatolia Geneworks, Turklab, Genkord, A1 Life Sciences, Bioeksen, DIAGEN, Sentromer,Nucleogene and BATM Advanced etc. During them, Pishtaz Teb is the largestproducer, which can produce two types of diagnostic kits are now mass-producedby knowledge-based companies, first one is the RT-PCR tests, 8 million of whichare being produced per month; while the other is serology-based tests that atotal of 400,000 are being manufactured monthly and is expected to reach up to2 million.


Duringall MENA countries, only Iran, Turkey and Israel have local producers. Iraq, Algeriaand Jordan can produce 2019-nCoV testing kit in lab and cannot produce in large-scale.Other countries in MENA are not able to produce 2019-nCoV testing kit.


Iranis most seriously COVID-19 affected country, with the highest number ofinfection and death cases in MENA. As of 9 o'clock on Jun. 24, 2020, a total of209,970 cases were diagnosed and 9,863 cases were dead in Iran. About 1475331people were tested in Iran.


Withconfirmed COVID-19 cases worldwide surpassing 6.4 million and continuing togrow, scientists are pushing forward with efforts to develop vaccines andtreatments to slow the pandemic and lessen the disease’s damage. An official atthe National Institutes of Health said in mid-May that large-scale testingcould begin in July with a vaccine potentially available by January.